Hemophagocytic Lymphohistiocytosis in Adults: A Retrospective Study in a Belgian Teaching Hospital

Halil Yildiz1, Diego Castanares-Zapatero2, Philippe d’Abadie3, Sarah Bailly4, Jean Cyr Yombi1

1Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium; 2Department of Intensive Care, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium; 3Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium; 4Department of Hematology, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium

Correspondence: Halil Yildiz, Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UClouvain, 10 Av Hippocrate, Bruxelles, 1200, Belgium, Email halil.yildiz@saintluc.uclouvain.be

Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a disease characterized by hyperactivation of macrophages, cytotoxic T lymphocytes and natural killer (NK) cells intense hyperimmune response as well as uncontrolled release of inflammatory cytokines.1,2 It is classically subdivided into primary HLH and secondary HLH.2 Primary HLH refers to pediatric patients with defects in genes implicated in the cytotoxic pathways of T and NK cells or in the eradication of Epstein Barr virus (EBV).3 Secondary or acquired HLH (sHLH) concerns adult’s patients who have the syndrome secondary to infection (viral: EBV and cytomegalovirus [CMV] mainly, but also after bacterial, fungal, or parasitic infections), malignancies (mainly lymphomas), or autoimmune diseases, such as systemic juvenile idiopathic arthritis, Adult Onset Still’s Diseases (AOSD) or systemic lupus erythematosus, pregnancy and even drug induced HLH (lamotrigine, checkpoint inhibitor, CAR-T cells).2,4 However, this classification is not exactly adapted since genetic mutations are also found in adult patients with secondary or acquired HLH

Keywords: hemophagocytic lymphohistiocytosis, macrophage activation syndrome, infection, autoimmune disease, malignancy, corticosteroid, tocilizumab, ruxolitinib, mortality
and a trigger (such as infection, autoimmune disease) is also found in pediatric patients with HLH.\textsuperscript{5-10} The North American Consortium for Histiocytosis (NACHO) proposed to categorized according to etiology rather than as primary or secondary:\textsuperscript{11} familial-HLH (genetic mutation), malignancy-HLH, Rheumatologic-HLH (macrophage activation syndrome in the context of autoimmune disease), iatrogenic-HLH (drug induced HLH), HLH with immune compromise and non-specific HLH without a clear genetic or infectious trigger (HLH-NOS, idiopathic). This last classification allows to better appreciate the complexity of HLH disease and gives a better information for the treatment decisions. However, this nomenclature of HLH diagnosis is still a matter of discussion/debate and needs to be validated.

Mortality of HLH in adult patients ranges from 26.5% to 74.8% according to studies and etiologies.\textsuperscript{4} Most of the studies are performed in pediatric patients, and studies in adult patients are scarce and mainly based on case reports and series (mostly in Asian patients). We performed a retrospective study in order to describe clinical and biological characteristics of HLH in a Belgian teaching hospital and attempt to look for variables associated with mortality.

Materials and Methods

Study Design and Patients

This retrospective study was performed at a teaching hospital of 1000 beds in Belgium. All cases of adult HLH, from December 2010 to April 2022, were reviewed. HLH diagnosis was made based on HLH-2004 criteria and Hscore. Patients with more than five HLH-2004 criteria and/or Hscore >80% were included in the study.

Ethical Issues

Our institutional ethics committee (Comité d’Ethique Hospitalo-Facultaire [CEHF], Cliniques Universitaires Saint-Luc, Brussels, Belgium) stated that a written consent is not needed for analyses of anonymized data, retrospective study and give its authorization (N°CEHF 2022/17MAI/211-HLHadult). Our study complies with the Declaration of Helsinki.

Data Collection

Using our institutional database Medical explorer v3r49b7, Epic electronic health record and the database of the department of internal medicine and hematology, we reviewed the medical records of all patients and collected the following data, HScore and HLH-2004 criteria (on admission), demographics, clinical and labs characteristics (on admission), diagnostic investigation (18F-fluorodeoxyglucose positron emission tomography computed tomography [18-F-FDG PET/CT], thoraco-abdominal CT scan), underlying diseases, treatment, mortality (outcome).

Statistical Analysis

All analyses were conducted using SPSS 27 software (IBM SPSS Statistics for Windows, Version 27.0, Armonk, NY: IBM Corp). Discrete variables were reported as numbers and corresponding percentages, while continuous variables were expressed as mean and standard deviations (SD). Categorical variables were compared using Pearson’s chi-square test or exact Fisher test, whereas differences between continuous variables were assessed using unpaired Student’s \( t \)-test. An univariate logistic regression was conducted to assess the association between selected variables and mortality. A multivariate logistic regression model, using a forward stepwise method, was performed. Results were expressed as odds ratio with 95% confidence intervals. P-values were two-sided, and <5\% was considered as significative.

Results

General Characteristics

Among 56 patients identified with suspected HLH, 52 were included in the final analysis (4 patients were excluded due to diagnosis other than HLH, 1 thrombotic microangiopathy, 1 medullary aplasia due to epidermoid cancer, 1 B-cell acute lymphocytic leukemia and 1 spleen infarction).

Mean age (SD) of patients was 48 (18) years old, and 29 patients were of male gender (56\%). Clinical manifestations are shown in Table 1. The most frequent clinical manifestations were fever (98\%), bicytopenia (92\%), thrombocytopenia (92\%). Hemophagocytosis was found in bone marrow in 100\% of patients. Splenomegal and hepatomegal were found
| Clinical and Biological Characteristics | Number of Patients (n = 52) |
|----------------------------------------|-----------------------------|
| Fever                                  | 51 (98%)                    |
| Splenomegaly                           | 35 (67%)                    |
| Cytopenia (at least two lineages)      | 48 (92%)                    |
| Anemia (Hb <9 g/dl)                    | 38 (73%)                    |
| Neutropenia (ANC <1000/µL)            | 26 (50%)                    |
| Thrombocytopenia (<100 000/ µL)        | 48 (92%)                    |
| Ferritin ≥500 µg/L                     | 52 (100%)                   |
| Hemophagocytosis                       | 52 (100%)                   |
| Hepatomegaly                           | 14 (27%)                    |
| Hypertriglyceridemia                   | 51 (98%)                    |
| Hypofibrinogenemia                     | 25 (48%)                    |
| Renal involvement, acute renal failure | 6 (14.2%)                   |
| Neurological symptoms                  | 3 (7.1%)                    |
| DIC*                                   | 16 (30.7%)                  |
| Pulmonary involvement, respiratory insufficiency | 1 (2.3%) |
| Peripheral lymphadenopathy             | 12 (28.5%)                  |

**Underlying conditions**

| Malignancy                             | 22 (42%)                    |
| Solid cancer                           | 1 (1.9%)                    |
| Hematological disease                  | 21 (40%)                    |
| B-cell lymphoma                        | 10 (19.2%)                  |
| T-cell lymphoma                        | 7 (13.5%)                   |
| Multicentric Castleman disease         | 1 (1.9%)                    |
| Acute leukemia                          | 3 (5.8%)                    |

**Infections**

| EBV                                    | 8 (15%)                     |
| CMV                                    | 2 (3.8%)                    |
| HIV                                    | 1 (1.9%)                    |
| HSV-1                                  | 2 (3.8%)                    |
| Dengue                                 | 2 (3.8%)                    |
| Parvovirus                             | 1 (1.9%)                    |
| Hepatitis A                            | 1 (1.9%)                    |
| Toxoplasmosis                          | 1 (1.9%)                    |
| Tuberculosis                           | 1 (1.9%)                    |

(Continued)
in 67% and 27%, respectively, while peripheral lymphadenopathy was found in 31% of patients. The underlying diseases associated with HLH are presented in Table 1. A malignancy related-HLH was found in 22 patients (42%). A solid cancer was found in 1 patient, while a hematological disease was found in 21 patients (21/22). The hematological diseases associated with HLH were as following, B-cell lymphoma [10/21], T-cell lymphoma [7/21], acute leukemia [3/21] and Castleman disease [1/21]. An infection related HLH was found in 20 patients (38.5%) and was mainly secondary to EBV [8/20]. Other infectious agents are shown in Table 1. A rheumatologic disease related HLH (macrophage activation syndrome) was found in 7 patients (13.5%) and was mainly secondary to AOSD [3/7]. Finally, 2 patients have idiopathic HLH (3.8%) and 1 patient had HLH secondary to pregnancy (1.9%). Table 2 shows clinical and biological characteristics according to etiologies.

### Table 1 (Continued).

| Clinical and Biological Characteristics | Number of Patients (n = 52) |
|----------------------------------------|----------------------------|
| Autoimmune diseases                    | 7 (13.5%)                  |
| Systemic lupus erythematosus           | 1 (1.9%)                   |
| Adult-onset still diseases             | 3 (5.8%)                   |
| Shulman disease                        | 1 (1.9%)                   |
| Scleroderma                            | 1 (1.9%)                   |
| Overlap syndrome                       | 1 (1.9%)                   |
| Pregnancy                              | 1 (1.9%)                   |
| Idiopathic                             | 3 (3.8%)                   |

**Note:** ISTH criteria of DIC was used (DIC was considered if score ≥ 5).

**Abbreviations:** ANC, Absolute Neutrophil Count; DIC, Disseminated Intravascular Coagulation; EBV, Epstein-Barr virus; CMV, Cytomegalovirus; HSV, Herpes Simplex Virus.

---

Table 2 Clinical and Labs Characteristics of Adult Patients with HLH According to Etiologies

| Variables     | Overall (n = 52) | Female (n = 23) | Male (n = 29) | p-value | M-HLH (n = 22) | I-HLH (n = 20) | MAS-HLH (N = 7) | Idiopathic-HLH (n = 2)* |
|---------------|-----------------|-----------------|---------------|---------|----------------|----------------|------------------|------------------------|
|               | Total Effective (%) or Mean (SD) | Total Effective (%) or Mean (SD) | Total Effective (%) or Mean (SD) | Total Effective (%) or Mean (SD) | Total Effective (%) or Mean (SD) | Total Effective (%) or Mean (SD) | Total Effective (%) or Mean (SD) | Total Effective (%) or Mean (SD) |
| Gender (male) | 29 (56%)        | /               | /             | /       | 14 (64%)       | 13 (65%)       | 0                | 2 (100%)               |
| Mean age (SD) | 48 (18)         | 45 (17)         | 50 (20)       | 0.27    | 56 (21)        | 42 (15)        | 39 (11)          | 43 (22)                |
| Fever         | 51 (98%)        | 23 (100%)       | 28 (97%)      | 0.37    | 22 (100%)      | 19 (95%)       | 7 (100%)         | 2 (100%)               |
| Splenomegaly  | 35 (67%)        | 14 (61%)        | 21 (72%)      | 0.38    | 16 (73%)       | 14 (70%)       | 3 (43%)          | 1 (50%)                |
| Hepatomegaly  | 14 (27%)        | 8 (35%)         | 6 (21%)       | 0.25    | 8 (36%)        | 3 (15%)        | 2 (29%)          | 0                      |
| Bicytopenia   | 48 (92%)        | 23 (100%)       | 25 (86%)      | 0.064   | 22 (100%)      | 17 (85%)       | 7 (100%)         | 1 (50%)                |
| ANC (mm³/µL)  | 4297 (4938)     | 4913 (5692)     | 3421 (3622)   | 0.28    | 4206 (4263)    | 4790 (5897)    | 4250 (5170)      | 460 (424)              |
| Hb (g/dl)     | 9.2 (1.9)       | 8.6 (1.3)       | 9.6 (2.2)     | 0.051   | 8.7 (1.6)      | 9.9 (2.3)      | 9.1 (1.4)        | 7.9 (1.5)              |
| Pt (mm³/µL)   | 69,784 (57,862) | 66,695 (50,416) | 72,551 (63,000) | 0.71    | 62,142 (58,454)| 70,950 (60,698) | 81,428 (54,859) | 55,000 (36,062)       |
| TG (mg/dl)    | 323 (128)       | 348 (138)       | 293 (111)     | 0.13    | 302 (119)      | 342 (115)      | 267 (130)        | 487 (269)              |
| Fib (mg/dl)   | 358 (264)       | 320 (284)       | 387 (230)     | 0.36    | 434 (303)      | 311 (252)      | 277 (164)        | 287 (251)              |

(Continued)
Overall mortality, mortality at 30 days and 90 days were as following, 24/52 (46%), 13/52 (25%) and 4/52 (10%).

Clinical and biological characteristics were quite similar between women and men despite a slightly male predominance (56%). However, overall mortality was higher in male patients (17/52) compared to female patients (7/52) (p 0.043). There was no difference in mortality at 30 days and 90 days (Table 2).

### Table 2 (Continued).

| Variables               | Overall   | Female     | Male       | M-MLH     | I-MLH     | MAS-MLH   | Idiopathic-MLH |
|-------------------------|-----------|------------|------------|-----------|-----------|------------|----------------|
|                         | (n = 52)  | (n = 23)   | (n = 29)   | (n = 22)  | (n = 20)  | (N = 7)    | (n = 2)*       |
| Ferritin µg/L           | 32315    | 13,346     | 46,345     | 49,630    | 13,587    | 14,978     | 4348           |
| ALAT (U/L)              | 285 (643)| 197 (181)  | 355 (846)  | 99 (120)  | 530 (985) | 199 (193)  | 101 (7.8)      |
| ASAT (U/L)              | 235 (119)| 246 (274)  | 355 (846)  | 198 (274) | 356 (495) | 259 (336)  | 120 (45)       |
| TBIL (mg/dl)            | 3.2 (5.8)| 4.6 (7.4)  | 2.1 (3.6)  | 2.6 (6.3) | 2.6 (3.2) | 2.1 (2.9)  | 9.6 (11.9)     |
| Albumin (mg/dl)         | 28 (5.9) | 28 (6.4)   | 29 (5.3)   | 29 (5.2)  | 27 (6.7)  | 27 (5.8)   | 31 (7.7)       |
| LDH (U/L)               | 1115 (1078)| 956 (838)  | 1241 (1235)| 1055 (972)| 1238 (1226)| 1085 (1207)| 314 (69)       |
| Corticosteroids         | 42 (81%) | 20 (57%)   | 22 (76%)   | 20 (91%)  | 12 (60%)  | 7 (100%)   | 2 (100%)       |
| Etoposide               | 8 (15%)  | 4 (17%)    | 4 (14%)    | 6 (27%)   | 1 (5%)    | 1 (14%)    | 0              |
| Rituximab               | 5 (10%)  | 2 (9%)     | 3 (10%)    | 2 (9%)    | 2 (10%)   | 1 (14%)    | 0              |
| Chemotherapy            | 14 (27%) | 8 (26%)    | 8 (28%)    | 14 (64%)  | 0         | 0          | 0              |
| Tocilizumab             | 3 (6%)   | 3 (13%)    | 0          | 0         | 0         | 3 (43%)    | 0              |
| Ruxolitinib             | 1 (2%)   | 1 (4%)     | 0          | 0         | 0         | 3 (43%)    | 0              |
| Overall mortality       | 24 (46%) | 7 (30%)    | 17 (59%)   | 14 (64%)  | 6 (30%)   | 2 (29%)    | 2 (100%)       |
| Mortality 30 days       | 13 (25%) | 3 (13%)    | 10 (34%)   | 9 (41%)   | 3 (15%)   | 0          | 1 (50%)        |
| Mortality 90 days       | 4 (10%)  | 1 (4%)     | 3 (16%)    | 2 (15%)   | 2 (12%)   | 0          | 0              |

Notes: *Statistical analysis have been performed to compare each subgroup but is not presented in the table since the number of patients in MAS-MLH and idiopathic—MLH is lower and this give less value to a statistical analysis. Analysis of NK-cell activity, soluble CD25 (sIL-2R), were not performed in patients since these tests were not available on our center.

Abbreviations: ANC, absolute neutrophil count; Hb, hemoglobin; Pt, platelet; Fib, fibrinogen; TBIL, total bilirubin level; TG, triglycerides; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; LDH, lactate dehydrogenase; M-MLH, malignancy-associated HLH; I-MLH, infection-associated HLH; MAS-MLH, macrophage activation syndrome; ULN, upper limits of normal.

Overall mortality, mortality at 30 days and 90 days were as following, 24/52 (46%), 13/52 (25%) and 4/52 (10%).

Clinical and biological characteristics were quite similar between women and men despite a slightly male predominance (56%). However, overall mortality was higher in male patients (17/52) compared to female patients (7/52) (p 0.043). There was no difference in mortality at 30 days and 90 days (Table 2).

**Comparison of Clinical and Labs Characteristics Between Patients with Malignancy-MLH (M-MLH) and Non Malignancy-MLH (nM-MLH)**

Clinical, Labs, evolution and treatment characteristics are presented in Table 3. Mean age (SD) of patients with M-MLH was 56 (21) years old compared to 41 (14) years old in patients with nM-MLH (p 0.003). ALAT and ASAT were more frequently elevated in the nM-MLH subgroup (77%) compared to M-MLH (50%) (p < 0.05). Chemotherapy and etoposide were more frequently given in the M-MLH subgroup (64% and 27% respectively) compared to nM-MLH subgroup (0% and 7% respectively) (p < 0.001 and 0.0042). Overall mortality and mortality at 30 days were higher in M-MLH subgroup (64% and 41%) compared to nM-MLH subgroup (33 and 13%) (p < 0.05).
| Variables      | Malignancy Related HLH (N = 22) | Non-Malignancy Related HLH (N = 30) | P-value |
|----------------|---------------------------------|-------------------------------------|---------|
| Gender (male)  | 14(64%)                         | 15(50%)                             | 0.33    |
| Mean age       | 56(21%)                         | 41(14%)                             | 0.003   |
| Fever          | 22(100%)                        | 29(97%)                             | 0.39    |
| Splenomegaly   | 16(73%)                         | 19(63%)                             | 0.48    |
| Hepatomegaly   | 8(36%)                          | 6(20%)                              | 0.19    |
| Bicytopenia    | 22(100%)                        | 26(87%)                             | 0.075   |
| ANC (mm³/µL)   | 4106(4361)                      | 4187(5431)                          | 0.85    |
| Hb (g/dl)      | 8.8(1.6)                        | 9.5(2.1)                            | 0.17    |
| Pt (mm³/µL)(SD)| 62,909(57,158)                  | 75,133(57,828)                      | 0.45    |
| TG (mg/dl)     | 302(119)                        | 338(134)                            | 0.32    |
| Fib (mg/dl)    | 429(296)                        | 304(223)                            | 0.089   |
| Ferritin (µg/L)| 57,051(221,153)                 | 13,194(14,561)                      | 0.28    |
| ALAT elevated  | 11 (50%)                        | 23 (77%)                            | 0.046   |
| ALAT (UI/L)    | 99(120)                         | 421(819)                            | 0.07    |
| ASAT elevated  | 11 (50%)                        | 23 (77%)                            | 0.046   |
| ASAT (UI/L)    | 119(198)                        | 319(435)                            | 0.05    |
| TBIL (mg/dl)   | 2.57(6.1)                       | 3.6(5.5)                            | 0.51    |
| Albumine (mg/dl)| 29(5.1)                     | 27(6.3)                             | 0.33    |
| LDH (UI/L)     | 1055(972,100)                   | 1159(1164)                          | 0.73    |
| DIC*           | 8(36%)                          | 8(27%)                              | 0.45    |
| Cortisosteroids| 20(91%)                         | 22(73%)                             | 0.11    |
| Etoposide      | 6(27%)                          | 2(7%)                               | 0.042   |
| Rituximab      | 2(9%)                           | 3(10%)                              | 0.91    |
| Chemotherapy   | 14(64%)                         | 0                                   | <0.001  |
| Tocilizumab    | 0                               | 3(10%)                              | 0.13    |
| Ruxolitinib    | 0                               | 1(3%)                               | 0.39    |
| Overall mortality | 14(64%)                      | 10(33%)                             | 0.030   |
| Mortality 30 days | 9(41%)                        | 4(13%)                              | 0.023   |
| Mortality 90 days | 2(15%)                        | 2(8%)                               | 0.45    |

**Notes:** ISTH criteria of DIC was used (DIC was considered if score ≥ 5). Analysis of NK-cell activity, soluble CD25 (sIL-2R), were not performed in patients since these tests were not available on our center.

**Abbreviations:** ANC, absolute neutrophil count; Hb, hemoglobin; Pt, platelet; Fib, fibrinogen; TBIL, total bilirubin level; TG, triglycerides; DIC, disseminated intravascular coagulation; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; LDH, lactate dehydrogenase; ULN, upper limits of normal.
Factors Associated with Mortality in Univariate and Multivariate Analysis

In univariate analysis, malignancy, male sex, age and disseminated intravascular coagulation (DIC) were significantly associated with mortality (p < 0.05). In multivariate analysis, age (odds ratio, 1.053; 95% confidence interval, 1.016–1.092; p 0.005) remains the only factor significantly associated with mortality. The results of univariate and multivariate analysis are available in Table 4.

Discussion

Data concerning factors associated with mortality in adult patients with HLH are scarce. Our study is, to our knowledge, one of the first concerning Belgian patients. In fact, most of the studies concerned patients in China, only few studies were performed in Europe (Germany and France). It is important to describe clinical features of adults patients with HLH in different settings to see if there is a difference in the clinical presentation, etiologies and outcome. In our study, we showed that malignancy HLH (M-HLH) is the most common cause of HLH followed by infectious HLH and autoimmune disease associated with HLH such as in previous series. Factors significantly associated with mortality were malignancy, male sex, age and disseminated intravascular coagulation (DIC) in univariate analysis, while only age remained significant in multivariate analysis. Identifying factors influencing mortality is important since this can lead physician to closer follow-up and adapt treatment.

M-HLH has been showed as being a risk factor for mortality in several studies. There is only 1 study which showed that non-malignancy HLH (nM-HLH) was associated with higher mortality compared to M-HLH. This was explained by 1) delay in the diagnosis in nM-HLH, 2) lack of a clear underlying condition causing HLH in the group of nM-HLH and 3) high number of tuberculosis-associated HLH which is well known to be associated with high mortality rate (>50%). Since malignancy HLH is associated with poor outcome, some authors suggested that chemotherapy containing etoposide, which is a drug proposed in the HLH-94 and 2004 protocol, may be associated with better outcome. Recently, Song et al. showed that in patients with lymphoma-associated HLH, those treated with chemotherapy containing etoposide have a better survival (p < 0.05).

Another factor associated with mortality in our study was male sex, and this have been described also in other studies. Several other factors have been described in different studies and are summarized in the Supplemental File (Table S1). Age seems to be a factor of mortality in our study; however, the age cut-off value varies according to studies ranging from age >50

Table 4 Factors Associated with Mortality in Adult Patient with HLH (Univariate and Multivariate Analysis)

| Variable     | Univariate | Multivariate |
|--------------|------------|--------------|
|              | OR         | 95% CI       | p-value | Adjusted OR | 95% CI | p-value |
| Malignancy   | 3.50       | 1.11–11.09   | 0.033   |             |        |         |
| Age          | 1.05       | 1.01–1.09    | 0.005   | 1.053       | 1.016–1.092 | 0.005 |
| Sex          | 0.31       | 0.097–0.98   | 0.046   |             |        |         |
| Mean ferritin| 1.00       | 1.00–1.00    | 0.230   |             |        |         |
| DIC          | 6.00       | 1.59–22.61   | 0.008   |             |        |         |
| Platelets    | 1.00       | 1.00–1.00    | 0.685   |             |        |         |
| Fibrinogen   | 0.99       | 0.99–1.00    | 0.309   |             |        |         |
| Albumin <20 g/L | 0.38     | 0.06–2.31   | 0.297   |             |        |         |
| Natremia     | 1.06       | 0.96–1.15    | 0.240   |             |        |         |
| Chemotherapy | 0.69       | 0.19–2.51    | 0.578   |             |        |         |

Abbreviations: OR, odds ratio; DIC, disseminated intravascular coagulation; CI, confidence interval.
Disseminated intravascular coagulation (DIC) is also associated with mortality, and it is not surprising since it means that organ damage is ongoing due to the severity of the disease.\textsuperscript{11–13,26,33} High ferritin and low albumin, hemoglobin and platelet level have also been described as a risk factor of mortality, but this was not confirmed in our study and the best cut-off value still needs to be determined.\textsuperscript{17,18,27}

Another interesting finding in our study was that alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) level were more frequently elevated in the nM-HLH subgroup (77\%) compared to M-HLH (50\%) (p < 0.05). This is probably explained by the infectious agent related HLH in the non-malignancy HLH subgroup (nM-HLH) which were microorganisms with liver tropism (EBV, CMV, Dengue, Herpes Simplex Virus, Tuberculosis).

Our study has several limitations. Firstly, this is a single center and retrospective study. Secondly, the number of patients was low (52 patients) and this may explain why DIC and malignancy failed to be significant factors associated with mortality in multivariate analysis. Despite these limitations, our results depict a valuable picture of the situation in a teaching high-volume center since data concerning Belgian patients are lacking. Thirdly, the diagnosis of DIC was made by using ISTH criteria.\textsuperscript{40} However, diagnosis of DIC in HLH is a challenge since HLH is associated with hypofibrinogenemia, thrombocytopenia and coagulation abnormalities. Other biological markers are required to better diagnose DIC in patients with HLH. Fourthly, the screening of genes related to primary HLH was not performed which does not exclude the possibility of presence of primary HLH in a minority of our patients.

\textbf{Conclusions}
We described a single center’s experience with adult patients with secondary HLH. The most frequent triggers were malignancy and infectious agent followed by rheumatologic disease. Risk factors for mortality were age, male sex, malignancy and disseminated intravascular coagulation. A prompt diagnosis and early treatment should be performed in order to improve outcome.

\textbf{Author Contributions}
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

\textbf{Funding}
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

\textbf{Disclosure}
The authors report no conflicts of interest in this work.

\textbf{References}
1. Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. \textit{Hematol Am Soc Hematol Educ Progr}. 2013;2013:605–11. doi:10.1182/asheducation-2013.1.605
2. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. \textit{Lancet}. 2014;383:1503–16. doi:10.1016/S0140-6736(13)61048-X
3. La Rosée P, Horne AC, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. \textit{Blood}. 2019;133:2465–2477. doi:10.1182/blood.201894618
4. Yildiz H, Van Den Neste E, Defour JP, Danse E, Yombi JC. Adult haemophagocytic lymphohistiocytosis: a review. \textit{QJM}. 2020;113(4):205–213.
5. Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. \textit{Br J Haematol}. 2016;174(2):203–217. doi:10.1111/bjh.14147
6. Zhang M, Behrens EM, Atkinson TP, Shakoory B, Grom AA, Cron RQ. Genetic defects in cytolysis in macrophage activation syndrome. \textit{Curr Rheumatol Rep}. 2014;16:439–446. doi:10.1007/s11926-014-0439-2
7. Carvelli J, Piperoglou C, Farnarier C, et al. Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect. \textit{Blood}. 2020;136(5):542–552. doi:10.1182/blood.2019003664
8. Miao Y, Zhu HY, Qiao C, et al. Pathogenic gene mutations or variants identified by targeted gene sequencing in adults with hemophagocytic lymphohistiocytosis. \textit{Front Immunol}. 2019;10:395. doi:10.3389/fimmu.2019.00395
9. Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult onset familial HLH. *Blood*. 2011;118(5):5794–8. doi:10.1182/blood-2011-07-370148

10. Chen X, Wang F, Zhang Y, et al. Genetic variant spectrum in 265 Chinese patients with hemophagocytic lymphohistiocytosis: molecular analyses of PRF1, UNC13D, STX11, STXBP2, SH2D1A and X1AP. *Clin Genet*. 2018;94:200–212. doi:10.1111/cge.13363

11. Tseng YT, Sheng WH, Lin BH, et al. Causes, clinical symptoms, and outcomes of infectious diseases associated with hemophagocytic lymphohistiocytosis in Taiwanese adults. *J Microbiol Immunol Infect*. 2011;44:191–7. doi:10.1016/j.jmii.2011.01.027

12. Park HS, Kim DY, Lee JH, et al. Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors. *Ann Hematol*. 2012;91:897–904. doi:10.1007/s00277-011-1380-3

13. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adult cases of hemophagocytic lymphohistiocytosis. *Mayo Clin Proc*. 2014;89(4):484–492. doi:10.1016/j.mayocp.2013.12.012

14. Rivière S, Galicier L, Coppo P, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. *Am J Med*. 2014;127:118–25. doi:10.1016/j.amjmed.2014.04.034

15. Li J, Wang Q, Zheng W, et al. Hemophagocytic lymphohistiocytosis, clinical analysis of 103 adult patients. *Medicine*. 2014;93:100–5. doi:10.1097/MD.0000000000000222

16. Lim SH, Park S, Jung JH, et al. Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. *Ann Hematol*. 2016;95:325–35. doi:10.1007/s00277-015-2523-8

17. Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. *Am J Hematol*. 2015;90:220–224. doi:10.1002/ajh.23911

18. Dholaria B, Hammond WA, Shreders A, Robinson S, Sher T. Hemophagocytic lymphohistiocytosis: retrospective analysis for prognostic factors. *Blood*. 2015;126:4615. doi:10.1182/blood-2015-07-661615

19. Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. *Br J Haematol*. 2016;172:412–419. doi:10.1111/bjh.13837

20. Zhou J, Wu ZQ, Qiao T, Xu HG. Development of laboratory parameters-based formulas in predicting short outcomes for adult hemophagocytic lymphohistiocytosis. *Diagn Interv Radiol*. 2016;22:471–5. doi:10.1515/dir.2016.15226

21. Zheng Y, Hu G, Liu Y, et al. The role of 18F-FDG PET CT in the management of patients with secondary haemophagocytic lymphohistiocytosis. *Clin Radiol*. 2016;71:1248–1254. doi:10.1016/j.crad.2016.05.011

22. Apodaca E, Rodríguez-Rodríguez S, Tuna-Aguiar EJ, Demichels-Gómez R. Prognostic factors and outcomes in adults with secondary hemophagocytic lymphohistiocytosis: a single-center experience. *Clin Lymphoma Myeloma Leuk*. 2018;18(10):e373–e380. doi:10.1016/j.clml.2018.06.014

23. Zhang Q, Li L, Zhu L, et al. Adult onset haemophagocytic lymphohistiocytosis prognosis is affected by underlying disease: analysis of a single-institution series of 174 patients. *Swiss Med Wkly*. 2018;148:w14641. doi:10.4414/smw.2018.14641

24. Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. *QJM*. 2018;111:23–31. doi:10.1093/qjmed/hcx183

25. Birndt S, Schen T, Heinevetter B, et al. Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. *J Cancer Res Clin Oncol*. 2020;146(4):1065–1077. doi:10.1007/s00432-020-03139-4

26. Dack ND, Kane BS, Fall S, et al. Adult hemophagocytic lymphohistiocytosis in sub-saharan area: a retrospective study of 26 cases. *Cureus*. 2020;12(3):e7258. doi:10.7759/cureus.7258

27. Sareen V, Liu J, Wang AM. Clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. *Leuk Lymphoma*. 2020;61(7):1592–1600. doi:10.1080/10428194.2020.1737684

28. Zhang FJ, Huang GQ, Li J, Xu J, Li XM, Wang AM. Clinical characteristics of adult hemophagocytic lymphohistiocytosis in the emergency department. *Int J Gen Med*. 2021;20(14):4687–4694. doi:10.2147/IGM.S26270

29. Zhou Y, Kong F, Wang S, et al. Increased levels of serum interleukin-10 are associated with poor outcome in adult hemophagocytic lymphohistiocytosis patients. *Orphanet J Rare Dis*. 2016;11(1):347. doi:10.1186/s13023-016-01973-4

30. Bichon A, Bourenne J, Allardet-Servent J, et al. High mortality of HLH in ICU regardless etiology or treatment. *Front Med*. 2021;6(8):735796. doi:10.3389/fmed.2021.735796

31. Zhou J, Wu ZQ, Qiao T, Xu HG. Development of laboratory parameters-based formulas in predicting short outcomes for adult hemophagocytic lymphohistiocytosis patients with different underlying diseases. *J Clin Immunol*. 2022;42:1000–1008. PMID: 35386042. doi:10.1007/s10875-022-01263-z

32. Brastianos PK, Swanson JW, Sperati J, Karakousis PC. Tuberculosis-associated haemophagocytic syndrome. *Lancet Infect Dis*. 2006;6(7):447–454. doi:10.1016/S1473-3099(06)70524-2

33. Zhang Y, Liang Q, Qin H, Li Y, Zeng X. Tuberculosis-associated hemophagocytic lymphohistiocytosis with initial presentation of fever of unknown origin in a general hospital: an analysis of 8 clinical cases. *Medicine*. 2017;96(16):e6575. doi:10.1097/MD.0000000000006575

34. Henter J-I, Samuelsson-Horne AC, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-04 immuno-chemotherapy and bone marrow transplantation. *Blood*. 2002;100:2367–2373. doi:10.1182/blood-2002-01-0172

35. Trottestam H, Horne A, Arico M, et al. Histioctye Society. Chemoinmunotherapy for hemophagocytic lymphangiitis: long-term results of the HLH-94 treatment protocol. *Blood*. 2011;118(17):4577–4584.

36. Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. *Blood*. 2017;130(25):2728–2738. doi:10.1182/blood-2017-06-788349
